Answers are grounded in this paper and cite their sources.
Our results confirm the impact of the CYP3A4*22 allele on TAC pharmacokinetics, as a second significant genetic factor (in addition to the CYP3A5*1 allele) influencing TAC dose-adjusted blood concentrations in kidney transplant recipients.
No takes yet. Share an insight, caveat, or question.
Kurzawski et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: